Bookmark and Share

Vertex Pharmaceuticals Shares Surge on Encouraging Clinical Data (VRTX)

Vertex Pharmaceuticals Incorporated (NASDAQ: VRTX), a biotechnology company engaged in the discovery, development, manufacturing and commercialization of small molecule drugs for the treatment of serious diseases, on Monday, reported that the new cystic fibrosis drug Kalydeco when combined with its experimental treatment for the disease led to substantially improved breathing ability in a mid-stage study.

VRTX shares surged following the announcement of the encouraging clinical data. The stock rose to an intra-day high of $58.75 before finishing the day 55.36% higher at $58.12 on above average volume of 40.22 million.

Dr. Joseph Pilewski, who is an adult cystic fibrosis physician at the University of Pittsburg Medical Center, said that this is very exciting data. Dr. Pilewski said that if this were to bear out in a Phase 3 pivotal trial it will dramatically impact the treatment options out there for patients with cystic fibrosis.

The data indicates that Vertex could have a multibillion dollar franchise in cystic fibrosis.

The study looked at 37 patients, who underwent 56 days of treatment with the Kalydeco/VX-809 combination and 11 patients, who underwent a placebo. The study found a statistically significant lung function improvement for those on the study drugs.

Chris Wright, M.D., Ph. D., Senior Vice President of Global Medicines Development and Medical Affairs at Vertex Pharmaceuticals, said that for the past 14 years, VRTX has been focused on learning about the underlying cause of cystic fibrosis so it can develop new medicines to help as many patients as possible and today VRTX believes that it is one step closer to this goal. Wright said that VRTX looks forward to starting discussions with regulatory agencies later this year when the company full data from the study, with the goal of moving forward with a pivotal study as quickly as possible.


Leave a Reply

  

  

  

You can use these HTML tags

<a href="" title=""> <abbr title=""> <acronym title=""> <b> <blockquote cite=""> <cite> <code> <del datetime=""> <em> <i> <q cite=""> <strike> <strong>


-------------------------------------------------------------------------------------------------------------------------
All stories in DailyStocks.com are for informational purposes only. This is NOT a stock recommendation. This DailyStocks.com story is a daily light analysis featuring a stock with insider buying. With some caveats, insiders purchase a stock because they think the stock is going up. There are other factors to consider such as size of the transaction relative to their compensation and net worth. Sometimes, insiders might be propping a stock price up for future financing. Sometimes, the amount of insider buying are misread or misreported. Each month, DailyStocks releases a a summary of the stocks with insider buying. Sign up for the free monthly newsletter at DailyStocks.com . About Dailystocks.com: DailyStocks.com is the place where you can find stories about stocks with insider buying, where you can educate yourself about stock market investing, and where you can perform the stock search engine analysis – you enter a stock symbol, and you get a resulting page of stock ticker indexed links so that you do not have to type the stock symbol each time.